» Articles » PMID: 18160420

Role of Pathogenic Auto-antibody Production by Toll-like Receptor 9 of B Cells in Active Systemic Lupus Erythematosus

Overview
Specialty Rheumatology
Date 2007 Dec 28
PMID 18160420
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Toll-like receptor 9 (TLR9) is a pattern-associated receptor functioning in innate immunity that may be involved in the recognition of self-antigens and the production of pathogenic auto-antibodies. Therefore, we examined the expression of TLR9 in systemic lupus erythematosus (SLE) to determine whether TLR9 is involved in the production of pathogenic auto-antibodies.

Methods: B cells were collected from patients with active SLE, and subjected to analysis of the TLR9 molecule using flow cytometry fluorescence activated cell sorting (FACS) and TLR9 mRNA by reverse-transcriptase polymerase chain reaction. SLE B cells were stimulated with CpG-ODN, and subsequent cytokine and anti-dsDNA antibody production was measured by enzyme-linked immunosorbent assay.

Results: The expression and mRNA level of TLR9 on B cells was up-regulated in SLE patients, and SLE disease activity index (SLEDAI) and CH50 were correlated with TLR9 expression on CD20+ B cells. Moreover, TLR9-CpG interaction enhanced the production of anti-dsDNA antibody and IL-10.

Conclusions: The present study demonstrated that higher expression of TLR9 on peripheral blood B cells from patients with active SLE was significantly correlated with CH50 and SLEDAI to TLR9, and induced the production of anti-dsDNA antibody and IL-10 by TLR9-CpG ligation. These results suggest that an abnormality of innate immunity plays a crucial role in the pathology of SLE, and that blockade of CpG-TLR9 interaction may be a new therapeutic approach for SLE.

Citing Articles

B cell development and antibody responses in human immune system mice: current status and future perspective.

Zhang T, Liu W, Yang Y Sci China Life Sci. 2024; 67(4):645-652.

PMID: 38270770 DOI: 10.1007/s11427-023-2462-8.


CD83 Regulates the Immune Responses in Inflammatory Disorders.

Riaz B, Islam S, Ryu H, Sohn S Int J Mol Sci. 2023; 24(3).

PMID: 36769151 PMC: 9917562. DOI: 10.3390/ijms24032831.


Increased Proportion of CD226 B Cells Is Associated With the Disease Activity and Prognosis of Systemic Lupus Erythematosus.

Nakano M, Ayano M, Kushimoto K, Kawano S, Higashioka K, Inokuchi S Front Immunol. 2021; 12:713225.

PMID: 34367178 PMC: 8334729. DOI: 10.3389/fimmu.2021.713225.


Meant to B: B cells as a therapeutic target in systemic lupus erythematosus.

Atisha-Fregoso Y, Toz B, Diamond B J Clin Invest. 2021; 131(12).

PMID: 34128474 PMC: 8203443. DOI: 10.1172/JCI149095.


Microvesicles in active lupus nephritis show Toll-like receptor 9-dependent co-expression of galectin-3 binding protein and double-stranded DNA.

Rasmussen N, Nielsen C, Nielsen C, Jacobsen S Clin Exp Immunol. 2020; 204(1):64-77.

PMID: 33354779 PMC: 7944362. DOI: 10.1111/cei.13569.